tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2026-104-1-114-125tiblj-1942Research ArticleОБЗОРREVIEWВ поисках идеального оксазолидинона для лечения туберкулезаSearching for Ideal Oxazolidinone for Treatment of Tuberculosishttps://orcid.org/0000-0002-3138-6538ГайдаА. И.GaydaA. I.

Гайда Анастасия Игоревна, к. м. н., старший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4, к. 2;

Тел.: +7 (495) 681-11-66

Anastasiya I. Gayda, Candidate of Medical Sciences, Senior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

2, 4 Dostoevskiy St., Moscow, 127473;

Phone: +7 (495) 681-11-66

nsovca@yandex.ruhttps://orcid.org/0000-0002-5396-7552МожокинаГ. Н.MozhokinaG. N.

Можокина Галина Николаевна, д. м. н., ведущий научный сотрудник лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции, ведущий научный сотрудник лаборатории фармакологии и химиотерапии

127473, Москва, ул. Достоевского, д. 4, к. 2;

Тел.: +7 (495) 681-11-66

Galina N. Mozhokina Doctor of Medical Sciences, Leading Researcher of Laboratory of Immunopathology and Immunodiagnostics and Tuberculosis Infection, Leading Researcher of Pharmacology and ChemotherapyLaboratory

2, 4 Dostoevskiy St., Moscow, 127473;

Phone: +7 (495) 681-11-66

mojokina@mail.ruhttps://orcid.org/0000-0001-7368-9695ПереверзеваЭ. Р.PereverzevaE. R.

Переверзева Элеонора Рафаиловна, д. б. н., главный научный сотрудник

127473, Москва, ул. Достоевского, д. 4, к. 2;

Тел.: +7 (495) 681-11-66

Eleonora R. Pereverzeva, Doctor of Biological Sciences, Chief Researcher

2, 4 Dostoevskiy St., Moscow, 127473:

Phone: +7 (495) 681-11-66

pereverzeva-ella@yandex.ruhttps://orcid.org/0000-0002-4132-0049РомановаМ. И.RomanovaM. I.

Романова Мария Игоревна Младший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4, к. 2;

Тел.: +7 (495) 681-11-66

Maria I. Romanova Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

2, 4 Dostoevskiy St., Moscow, 127473;

Phone: +7 (495) 681-11-66

romanovaMI@nmrc.ruhttps://orcid.org/0000-0002-9621-9271АбрамченкоА. В.AbramchenkoA. V.

Абрамченко Анна Валентиновна, младший научный сотрудник отдела дифференциальной диагностики лечения туберкулеза и сочетанных инфекций, ассистент кафедры фтизиатрии

127473, Москва, ул. Достоевского, д. 4, к. 2;

Тел.: +7 (495) 681-11-66

Anna V. Abramchenko, Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections Assistant of Phthisiology Department

2, 4 Dostoevskiy St., Moscow, 127473;

Phone: +7 (495) 681-11-66

av.abramchenko@mail.ruhttps://orcid.org/0000-0001-6596-9777СамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна, д. м. н., заместитель директора по науке

127473, Москва, ул. Достоевского, д. 4, к. 2;

Тел.: +7 (495) 681-11-66

Anastasiya G. Samoylova, Doctor of Medical Sciences, Deputy Director for Research

2, 4 Dostoevskiy St., Moscow, 127473;

Phone: +7 (495) 681-11-66

a.samoilova.nmrc@mail.ruФГБУ «Национальный медицинский исследовательский центр Фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthRussian FederationФГБУ «Национальный медицинский исследовательский центр Фтизиопульмонологии и инфекционных заболеваний» МЗ РФ; ФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе»РоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; G.F. Gause Research Institute for Development of New AntibioticsRussian FederationФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе»РоссияG.F. Gause Research Institute for Development of New AntibioticsRussian FederationФГБУ «Национальный медицинский исследовательский центр Фтизиопульмонологии и инфекционных заболеваний» МЗ РФ; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of HealthRussian Federation2026220320261041114125Copyright © Гайда А.И., Можокина Г.Н., Переверзева Э.Р., Романова М.И., Абрамченко А.В., Самойлова А.Г., 20262026Гайда А.И., Можокина Г.Н., Переверзева Э.Р., Романова М.И., Абрамченко А.В., Самойлова А.Г.Gayda A.I., Mozhokina G.N., Pereverzeva E.R., Romanova M.I., Abramchenko A.V., Samoylova A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1942

Оксазолидиноны представляют собой перспективный класс препаратов для терапии туберкулеза с множественной лекарственной устойчивостью (МЛУ-ТБ). Линезолид, первый представитель класса, высокоэффективен, однако, его применение ограничено токсичностью (миелосупрессия, нейропатия). Проанализированы 63 научных источника в поисках новых оксазолидинонов для лечения туберкулеза. Новые препараты и соединения (тедизолид, сутезолид, контезолид, дельпазолид, TBI-223) обладают более благоприятным профилем безопасности при сходной с линезолидом или даже повышенной антимикобактериальной активностью. Эти соединения в ближайшие годы могут стать новой составляющей частью коротких безопасных и эффективных схем химиотерапии туберкулеза.

Oxazolidinones represent a promising class of drugs for treatment of multidrug-resistant tuberculosis (MDR-TB). Linezolid, the first representative of this class, is highly effective; however, its use is limited due to its toxicity (myelosuppression, neuropathy). 63 publications were analyzed in order to search for new oxazolidinones for treatment of tuberculosis. New drugs and compounds (tedizolid, sutezolid, contezolid, delpazolid, and TBI-223) have a more favorable safety profile with antimycobacterial activity similar to or even greater than that of linezolid. In the coming years, these compounds may become an important component of short, safe, and effective chemotherapy regimens for tuberculosis.

туберкулез с множественной лекарственной устойчивостьюоксазолидиноныновые препараты и соединенияmultidrug-resistant tuberculosisoxazolidinonesnew drugs and compoundsReferencesАмизолид (линезолид). Информация о лекарственном препарате. – [Электронный ресурс]. URL: https://yotta.vademec.ru/drugs/amizolid/ [Дата обращения: 14.06.2025]Amizolid (linezolid). Information about the medicinal product. (In Russ.) Epub. Available: https://yotta.vademec.ru/drugs/amizolid/Accessed June 14, 2025Никода В.В., Кузнецова С.М., Прусова А.С. Клинические и микробиологические особенности тедизолида – нового представителя группы оксазолидинонов // Фарматека. – 2017. – № 17. – C. 10.Nikoda V.V., Kuznetsova S.M., Prusova A.S. Clinical and microbiological features of tedizolid, a new product from the oxazolidinone group. Pharmateka, 2017, no. 17, pp. 10. (In Russ.)Русских А.Е., Кутузова Д.М., Ловачева О.В., Самойлова А.Г., Васильева И.А. Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы // Туберкулез и болезни легких. – 2020. – Т. 98, № 12. – Р. 57-66.Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 12, pp. 57-66. (In Russ.)Ali M.Z., Dutt T.S., MacNeill A., Walz A., Pearce C., Lam H., Philp J., Patterson J., Henao-Tamayo M., Lee R.E., Liu J., Robertson G.T., Hickey A.J., Meibohm B., Gonzalez-Juarrero M.A. Modified B.P.L. Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides. bioRxiv. – 2023. – Vol. 11, № 16. – Р. 567434. https://doi.org/10.1101/2023.11.16.567434Ali M.Z., Dutt T.S., MacNeill A., Walz A., Pearce C., Lam H., Philp J., Patterson J., Henao-Tamayo M., Lee R.E., Liu J., Robertson G.T., Hickey A.J., Meibohm B., Gonzalez-Juarrero M.A. Modified B.P.L. regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. bioRxiv, 2023, vol. 11, no. 16, pp. 567434. https://doi.org/ 10.1101/2023.11.16.567434Alsultan A., Furin J.J., Du Bois J., van Brakel E., Chheng P., Venter A., Thiel B., Debanne S.A., Boom W.H., Diacon A.H., Johnson J.L., Peloquin C.A. Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis // Antimicrob Agents Chemother. – 2017. – Vol. 61, № 10. – Р. e01066-17. https://doi.org/10.1128/AAC.01066-17Alsultan A., Furin J.J., Du Bois J., van Brakel E., Chheng P., Venter A., Thiel B., Debanne S.A., Boom W.H., Diacon A.H., Johnson J.L., Peloquin C.A. Population pharmacokinetics of AZD-5847 in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2017, vol. 61, no. 10, pp. e01066-17. https://doi.org/10.1128/AAC.01066-17Angula K.T., Legoabe L.J., Beteck R.M. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review // Pharmaceuticals (Basel). – 2021. – Vol. 14, № 5. – Р. 461. https://doi.org/10.3390/ph14050461Angula K.T., Legoabe L.J., Beteck R.M. Chemical classes presenting novel antituberculosis agents currently in different phases of drug development: a 2010-2020 review. Pharmaceuticals (Basel), 2021, vol. 14, no. 5, pp. 461. https://doi.org/10.3390/ph14050461Application for addition of tedizolid phosphate to the WHO Model List of Essential Medicines. World Health Organization. – EML Expert Committee Meeting, 2023. Available at: https://list.essentialmeds.org/recommendations/1165 [Accessed 27.09.2025].Application for addition of tedizolid phosphate to the WHO Model List of Essential Medicines.World Health Organization. EML Expert Committee Meeting, 2023. Available: https://list.essentialmeds.org/recommendations/1165 Accessed September 27, 2025Assistance Publique – Hôpitaux de Paris. Evaluation of the Early Bactericidal Activity of Tedizolid Phosphate Compared with Linezolid and Standard Tuberculosis Therapy in Adult Patients with Drug-Susceptible Pulmonary Tuberculosis: clinical trial NCT05534750. Available at: ClinicalTrials.gov [Accessed 24.07.2025].Assistance Publique – Hôpitaux de Paris. Evaluation of the Early Bactericidal Activity of Tedizolid Phosphate Compared with Linezolid and Standard Tuberculosis Therapy in Adult Patients with Drug-Susceptible Pulmonary Tuberculosis: clinical trial NCT05534750. Available: ClinicalTrials.gov Accessed July 24, 2025Balasubramanian V., Solapure S., Iyer H., Ghosh A., Sharma S., Kaur P., Deepthi R., Subbulakshmi V., Ramya V., Ramachandran V., Balganesh M., Wright L., Melnick D., Butler S.L., Sambandamurthy V.K. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis // Antimicrob Agents Chemother. – 2014. – Vol. 58, № 1. – Р. 495-502. https://doi.org/10.1128/AAC.01903-13Balasubramanian V., Solapure S., Iyer H., Ghosh A., Sharma S., Kaur P., Deepthi R., Subbulakshmi V., Ramya V., Ramachandran V., Balganesh M., Wright L., Melnick D., Butler S.L., Sambandamurthy V.K. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother., 2014, vol. 58, no. 1, pp. 495-502. https://doi.org/10.1128/AAC.01903-13Barbachyn M.R., Hutchinson D.K., Brickner S.J., Cynamon M.H., Kilburn J.O., Klemens S.P., Glickman S.E., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., Zurenko G.E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity // J Med Chem. – 1996. – Vol. 39, № 3. – Р. 680-685. https://doi.org/10.1021/jm950956yBarbachyn M.R., Hutchinson D.K., Brickner S.J., Cynamon M.H., Kilburn J.O., Klemens S.P., Glickman S.E., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., Zurenko G.E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem., 1996, vol. 39, no. 3, pp. 680-685. https://doi.org/10.1021/jm950956yBruinenberg P., Nedelman J., Yang T.J., Pappas F., Everitt D. Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects // Antimicrob Agents Chemother. – 2022. – Vol. 66, № 4. – Р. e0210821. https://doi.org/10.1128/aac.02108-21Bruinenberg P., Nedelman J., Yang T.J., Pappas F., Everitt D. Single ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of sutezolid in healthy adult subjects. Antimicrob. Agents Chemother., 2022, vol. 66, no. 4, pp. e0210821. https://doi.org/10.1128/aac.02108-21Chen R.H., Burke A., Cho J.G., Alffenaar J.W., Davies Forsman L. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? // Pharmaceutics. –2024. – Vol. 16, № 6. https://doi.org/10.3390/pharmaceutics16060818Chen R.H., Burke A., Cho J.G., Alffenaar J.W., Davies Forsman L. New oxazolidinones for tuberculosis: are novel treatments on the horizon? Pharmaceutics, 2024, vol. 16, no. 6. https://doi.org/10.3390/pharmaceutics16060818Cho Y.L., Jang J. Development of Delpazolid for the Treatment of Tuberculosis // Applied Sciences. – 2020. – Vol. 10, № 7. – Р. 2211. https:// doi.org/10.3390/app10072211Cho Y.L., Jang J. Development of delpazolid for the treatment of tuberculosis. Applied Sciences, 2020, vol. 10, no. 7, pp. 2211. https://doi.org/10.3390/app10072211Cho Y.S., Lim H.S., Lee S.H., Cho Y.L., Nam H.S., Bae K.S., et al. Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers // Antimicrob Agents Chemother. – 2018. – Vol. 62, № 7. – Р. se00451-se00518. https://doi.org/10.1128/AAC.00451-18Cho Y.S., Lim H.S., Lee S.H., Cho Y.L., Nam H.S., Bae K.S. et al. Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers. Antimicrob. Agents Chemother., 2018, vol. 62, no. 7, pp. se00451-se00518. https://doi.org/10.1128/AAC.00451-18Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. – World Health Organization. – Geneva: World Health Organization, 2014 (WHO/HTM/TB/2014.11) Available at: apps.who.int [Accessed 10.09.2025].Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. Geneva, World Health Organization, 2014 (WHO/HTM/TB/2014.11) Available: apps.who.int Accessed September 10, 2025Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R. McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M.; ZeNix Trial Team. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis // N Engl J Med. – 2022. – Vol. 387, № 9. – Р. 810-823. https://doi.org/10.1056/NEJMoa2119430Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R. McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M.; ZeNix Trial Team. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med., 2022, vol. 387, no. 9, pp. 810-823. https://doi.org/10.1056/NEJMoa2119430Contezolid (MRX-I) clinical trials for bone and joint and tuberculosis treatment // DrugBank. – Available at:https://go.drugbank.com [Accessed 16.06.2025].Contezolid (MRX-I) clinical trials for bone and joint and tuberculosis treatment. DrugBank. Available:https://go.drugbank.com Accessed June 16, 2025Delpazolid (LCB01-0371) // MedPath. – Available at: https://trial.medpath.com [Accessed 27.06.2025]Delpazolid (LCB01-0371). MedPath. Available: https://trial.medpath.com Accessed June 27, 2025Deshpande D., Srivastava S., Nuermberger E., Koeuth T., Martin K.R., Cirrincione K.N., Lee P.S., Gumbo T. Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis // Clin Infect Dis. – 2018. – Vol. 67. – S3. – Р. 342-S348. https://doi.org/10.1093/cid/ciy612Deshpande D., Srivastava S., Nuermberger E., Koeuth T., Martin K.R., Cirrincione K.N., Lee P.S., Gumbo T. Multiparameter Responses to tedizolid monotherapy and moxifloxacin combination therapy models of children with intracellular tuberculosis. Clin. Infect. Dis., 2018, vol. 67, S3, pp. 342-S348. https://doi.org/10.1093/cid/ciy612Dierig A., Hoelscher M., Schultz S., Hoffmann L., Jarchow-MacDonald A., Svensson E.M., Te Brake L., Aarnoutse R., Boeree M., McHugh T.D., Wildner L.M., Gong X., Phillips P., Minja L.T., Ntinginya N., Mpagama S., Liyoyo A., Wallis R.S., Sebe M., Mhimbira F.A., Mbeya B., Rassool M., Geiter L., Cho Y.L., Heinrich N. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis // Trials. – 2023. – Vol. 24, № 1. – Р. 382. https://doi.org/10.1186/s13063-023-07354-5Dierig A., Hoelscher M., Schultz S., Hoffmann L., Jarchow-MacDonald A., Svensson E.M., Te Brake L., Aarnoutse R., Boeree M., McHugh T.D., Wildner L.M., Gong X., Phillips P., Minja L.T., Ntinginya N., Mpagama S., Liyoyo A., Wallis R.S., Sebe M., Mhimbira F.A., Mbeya B., Rassool M., Geiter L., Cho Y.L., Heinrich N. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials, 2023, vol. 24, no. 1, pp. 382. https://doi.org/10.1186/s13063-023-07354-5Dong J., Cheng Q., Tang C., Zhong Y., Wang J., Lv M., Chen Z., Li P., Luo M., Pei H. Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, China // Pathogens. – 2025. – Vol. 14, № 3. –Р. 218. https://doi.org/10.3390/pathogens14030218Dong J., Cheng Q., Tang C., Zhong Y., Wang J., Lv M., Chen Z., Li P., Luo M., Pei H. Comparative in vitro drug susceptibility study of five oxazolidinones against Mycobacterium tuberculosis in Hainan, China. Pathogens, 2025, vol. 14, no. 3, pp. 218. https://doi.org/10.3390/pathogens14030218Fernandes G.F.S., Scarim C.B., Kim S.H., Wu J., Castagnolo D. Oxazolidinones as versatile scaffolds in medicinal chemistry // RSC Med Chem. – 2023. – Vol. 14, № 5. – Р. 823-847. https://doi.org/10.1039/d2md00415aFernandes G.F.S., Scarim C.B., Kim S.H., Wu J., Castagnolo D. Oxazolidinones as versatile scaffolds in medicinal chemistry. RSC Med. Chem., 2023, vol. 14, no. 5, pp. 823-847. https://doi.org/10.1039/d2md00415aFlanagan S., Bartizal K., Minassian S.L., Fang E., Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions // Antimicrob Agents Chemother – 2013. – Vol. 57, № 7. – Р. 3060-3066. https://doi.org/10.1128/AAC.00431-13Flanagan S., Bartizal K., Minassian S.L., Fang E., Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob. Agents Chemother., 2013, vol. 57, no. 7, pp. 3060-3066. https://doi.org/ 10.1128/AAC.00431-13Flanagan S., McKee E.E., Rastogi N.K., Talley A.K., Fang E., Baker T.M., Marr J., Stryjewski M.E., Prokocimer P. Nonclinical and clinical evidence that tedizolid phosphate is safe with potentially less myelosuppression than linezolid // Antimicrobial Agents and Chemotherapy. – 2015. – Vol. 59, № 11. – P. 6472-6480. – https://doi.org/10.1128/AAC.00916-15;Flanagan S., McKee E.E., Rastogi N.K., Talley A.K., Fang E., Baker T.M., Marr J., Stryjewski M.E., Prokocimer P. Nonclinical and clinical evidence that tedizolid phosphate is safe with potentially less myelosuppression than linezolid. Antimicrobial Agents and Chemotherapy, 2015, vol. 59, no. 11, pp. 6472-6480. https://doi.org/10.1128/AAC.00916-15;Furin J.J., Du Bois J., van Brakel E., Chheng P., Venter A., Peloquin C.A., Alsultan A., Thiel B.A., Debanne S.M., Boom W.H., Diacon A.H., Johnson J.L. Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis // Antimicrob Agents Chemother. – 2016. – Vol. 60, № 11. – Р. 6591-6599. https://doi.org/10.1128/AAC.01163-16Furin J.J., Du Bois J., van Brakel E., Chheng P., Venter A., Peloquin C.A., Alsultan A., Thiel B.A., Debanne S.M., Boom W.H., Diacon A.H., Johnson J.L. Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2016, vol. 60, no. 11, pp. 6591-6599. https://doi.org/10.1128/AAC.01163-16Gao T., Yao C., Shang Y., Su R. Zhang X., Ren W., Li S., Shu W., Pang Y., Li Q. Antimicrobial Effect of Oxazolidinones and Its Synergistic Effect with Bedaquiline Against Mycobacterium abscessus Complex // Infect Drug Resist. – 2023. – Vol. 14. – № 16. – Р. 279-287. https://doi.org/10.2147/IDR.S395750Gao T., Yao C., Shang Y., Su R. Zhang X., Ren W., Li S., Shu W., Pang Y., Li Q. Antimicrobial effect of oxazolidinones and its synergistic effect with bedaquiline against Mycobacterium abscessus complex. Infect Drug Resist., 2023, vol. 14, no. 16, pp. 279-287. https://doi.org/10.2147/IDR.S395750History. LegoChem Biosciences. – Orphan Drug (07.2017) и Fast Track (01.2018) от FDA. – Available at: https://www.legochembio.com [Accessed 10.06.2025].History. LegoChem Biosciences. Orphan Drug (07.2017) и Fast Track (01.2018) from FDA. Available: https://www.legochembio.com Accessed June 10, 2025Iqbal K., Milioudi A., Wicha S.G. Pharmacokinetics and Pharmacodynamics of Tedizolid // Clin Pharmacokinet. – 2022. – Vol. 61, № 4. – Р. 489-503. https://doi.org/10.1007/s40262-021-01099-7Iqbal K., Milioudi A., Wicha S.G. Pharmacokinetics and pharmacodynamics of tedizolid. Clin. Pharmacokinet., 2022, vol. 61, no. 4, pp. 489-503. https://doi.org/10.1007/s40262-021-01099-7Jeong J.W., Jung S.J., Lee H.H., Kim Y.Z., Park T.K., Cho Y.L., et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone // Antimicrob Agents Chemother. – 2010. – Vol. 54, № 12. – P.5359-5362. https://doi.org/10.1128/AAC.00723-10Jeong J.W., Jung S.J., Lee H.H., Kim Y.Z., Park T.K., Cho Y.L. et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob. Agents Chemother., 2010, vol. 54, no. 12, pp. 5359-5362. https://doi.org/10.1128/AAC.00723-10Johnson T.M., Rivera C.G., Lee G., Zeuli J.D. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis // J Clin Tuberc Other Mycobact Dis. –2024. – № 37.1 – Р. 00470. https://doi.org/10.1016/j.jctube.2024.100470Johnson T.M., Rivera C.G., Lee G., Zeuli J.D. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. J. Clin. Tuberc. Other Mycobact. Dis., 2024, no. 37.1, pp. 00470. https://doi.org/10.1016/j.jctube.2024.100470Kim J.S., Kim Y.H., Lee S.H., Kim Y.H., Kim J.W., Kang J.Y., et al. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis // Antimicrob Agents Chemother. – 2022. – Vol. 66, № 2. – Р. e01684-21. https://doi.org/10.1128/AAC.01684-21Kim J.S., Kim Y.H., Lee S.H., Kim Y.H., Kim J.W., Kang J.Y. et al. Early bactericidal activity of delpazolid (LCB01-0371) in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2022, vol. 66, no. 2, pp. e01684-21. https://doi.org/10.1128/AAC.01684-21Kim T., Chang I., Kwon H., Kim M., Lee S., Park Y., Kim S. Pharmacokinetics, toxicity, and tolerability of tedizolid phosphate: results from a bridging study in healthy Korean subjects // Infection & Chemotherapy. – 2017. – Vol. 49, № 3. – P. 198-205. https://doi.org/10.3947/ic.2017.49.3.198Kim T., Chang I., Kwon H., Kim M., Lee S., Park Y., Kim S. Pharmacokinetics, toxicity, and tolerability of tedizolid phosphate: results from a bridging study in healthy Korean subjects. Infection & Chemotherapy, 2017, vol. 49, no. 3, pp. 198-205. https://doi.org/10.3947/ic.2017.49.3.198Kim T.S., Choe J.H., Kim Y.J., Yang C.S., Kwon H.J., Jeong J., Kim G., Park D.E., Jo E.K., Cho Y.L., et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus // Antimicrob Agents Chemother. – 2017. – 61. – Р. e02752-e02816.Kim T.S., Choe J.H., Kim Y.J., Yang C.S., Kwon H.J., Jeong J., Kim G., Park D.E., Jo E.K., Cho Y.L. et al. Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus. Antimicrob. Agents Chemother., 2017, 61, pp. e02752-e02816.Lan S.H., Lin W.T., Chang S.P., Lu L.C., Chao C.M., Lai C.C., Wang J.H. Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis // Antibiotics (Basel). – 2019. – Vol. 8, № 3. – Р. 137. https://doi.org/10.3390/antibiotics8030137Lan S.H., Lin W.T., Chang S.P., Lu L.C., Chao C.M., Lai C.C., Wang J.H. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. Antibiotics (Basel), 2019, vol. 8, no. 3, pp. 137. https://doi.org/10.3390/antibiotics8030137Lee J.Y., Shin J., Shin J.H., Chung J.W. In Vitro Activity of Tedizolid and Linezolid against Mycobacterium tuberculosis Complex and Nontuberculous Mycobacteria // Antimicrobial Agents and Chemotherapy. – 2017. – № 61. – Р. e01939. https://doi.org/10.1128/AAC.0193918Lee J.Y., Shin J., Shin J.H., Chung J.W. In Vitro activity of tedizolid and linezolid against Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Antimicrobial Agents and Chemotherapy, 2017, no. 61, pp. e01939. https://doi.org/10.1128/AAC.0193918Lee S.M., Choi S.C., Mun K.R., Seo J.Y., Cho Y.L., Shim T.S., Lim H.S. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01-0371) in Adult Patients with Pulmonary Tuberculosis // J Clin Pharmacol. – 2024. – Vol.64, № 7. – P.849-859. https://doi.org/10.1002/jcph.2424Lee S.M., Choi S.C., Mun K.R., Seo J.Y., Cho Y.L., Shim T.S., Lim H.S. Pharmacokinetic and pharmacodynamic modeling analysis of delpazolid (LCB01-0371) in adult patients with pulmonary tuberculosis. J. Clin. Pharmacol., 2024, vol. 64, no. 7, pp. 849-859. https://doi.org/10.1002/jcph.2424Michalik M., Lorenc T., Marcinkowski K., Muras M., Mikszta N., Mikszta J., Kantor K., Marcinkowska J. Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review // GMS Hyg Infect Control. – 2025. – № 20. – Р. 33. https://doi.org/10.3205/dgkh000562Michalik M., Lorenc T., Marcinkowski K., Muras M., Mikszta N., Mikszta J., Kantor K., Marcinkowska J. Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review. GMS Hyg. Infect. Control., 2025, no. 20, pp. 33. https://doi.org/10.3205/dgkh000562Michalska K., Lewandowska K., Mizera M., Bocian W., Pałys B., Cielecka-Piontek J. Spectroscopic identification of intermediates and final products of the chiral pool synthesis of sutezolid // J. Mol. Struct. – 2020. – № 1217. – Р. 128396 https://doi.org/10.1016/j.molstruc.2020.128396Michalska K., Lewandowska K., Mizera M., Bocian W., Pałys B., Cielecka-Piontek J. Spectroscopic identification of intermediates and final products of the chiral pool synthesis of sutezolid. J. Mol. Struct., 2020, no. 1217, pp. 128396 https://doi.org/10.1016/j.molstruc.2020.128396MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for contezolid and contezolid acefosamil // MicuRx Pharmaceuticals. – Published: 18.12.2022. – Available at: https://www.micurx.com/1641.html [Accessed 16.06.2025].MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for contezolid and contezolid acefosamil. MicuRx Pharmaceuticals, Published 18.12.2022. Available: https://www.micurx. com/1641.html Accessed June 06, 2025Milosevic T.V., Payen V.L., Sonveaux P., Muccioli G.G., Tulkens P.M., Van Bambeke F. Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes Antimicrob Agents // Chemother. – 2018. – Vol. 62, № 3. – Р. e01599-01617. https://doi.org/10.1128/AAC.01599-17Milosevic T.V., Payen V.L., Sonveaux P., Muccioli G.G., Tulkens P.M., Van Bambeke F. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes antimicrob agents. Chemother., 2018, vol. 62, no. 3, pp. e01599-01617. https://doi.org/ 10.1128/AAC.01599-17Molina-Torres C.A., Barba-Marines A., Valles-Guerra O., Ocampo-Candiani J., Cavazos-Rocha N., Pucci M.J., Castro-Garza J., Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages // Ann Clin Microbiol Antimicrob. – 2014. – № 13. – Р. 13. https://doi.org/10.1186/1476-0711-13-13Molina-Torres C.A., Barba-Marines A., Valles-Guerra O., Ocampo-Candiani J., Cavazos-Rocha N., Pucci M.J., Castro-Garza J., Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann. Clin. Microbiol. Antimicrob., 2014, no. 13, pp. 13. https://doi.org/10.1186/1476-0711-13-13Negatu D.A., Aragaw W.W., Cangialosi J., Dartois V., Dick T. Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections // Antimicrob Agents Chemother. – 2023. – Vol. 67, № 4. – Р. e0165522. https://doi.org/10.1128/aac.01655-22Negatu D.A., Aragaw W.W., Cangialosi J., Dartois V., Dick T. Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections. Antimicrob. Agents Chemother., 2023, vol. 67, no. 4, pp. e0165522. https://doi.org/10.1128/aac.01655-22Poon Y.K., La Hoz R.M., Hynan L.S., Sanders J., Monogue M.L. Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients // Open Forum Infect Dis. – 2021. – Vol. 8, № 4. – Р. ofab093. https://doi.org/10.1093/ofid/ofab093Poon Y.K., La Hoz R.M., Hynan L.S., Sanders J., Monogue M.L. Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients. Open Forum Infect. Dis., 2021, vol. 8, no. 4, pp. ofab093. https://doi.org/10.1093/ofid/ofab093Shaw K.J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C.M., Shinabarger D., Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains // Antimicrob Agents Chemother. – 2008. – Vol. 52, № 12. – Р. 4442-4447. https://doi.org/10.1128/AAC.00859-08Shaw K.J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C.M., Shinabarger D., Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother., 2008, vol. 52, no. 12, pp. 4442-4447. https://doi.org/10.1128/AAC.00859-08Shaw T.D., Smyth M., Turner G., Hunter M. Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection // J. Clin. Tuberc. Other Mycobact. Dis. –2021. – № 24. – Р. 100261. https://doi.org/10.1016/j.jctube.2021.100261Shaw T.D., Smyth M., Turner G., Hunter M. Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection. J. Clin. Tuberc. Other Mycobacter. Dis., 2021, no. 24, pp. 100261. https://doi.org/10.1016/j.jctube.2021.100261Soriano A., Miró O., Mensa J. Mitochondrial toxicity associated with linezolid // N Engl J Med. – 2005. – Vol. 353, № 21. – Р. 2305-2306. https://doi.org/10.1056/NEJM200511243532123Soriano A., Miró O., Mensa J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med., 2005, vol. 353, no. 21, pp. 2305-2306. https://doi.org/10.1056/NEJM200511243532123Srivastava S., Cirrincione K.N., Deshpande D., Gumbo T. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis. – Front Pharmacol. – 2021. – № 11. – Р. 616294. https://doi.org/10.3389/fphar.2020.616294Srivastava S., Cirrincione K.N., Deshpande D., Gumbo T. Tedizolid, faropenem, and moxifloxacin combination with potential activity against nonreplicating Mycobacterium tuberculosis. Front Pharmacol., 2021, no. 11, pp. 616294. https://doi.org/10.3389/fphar.2020.616294Srivastava S., Wang J.Y., Magombedze G., Chapagain M., Huang H.L., Deshpande D., Heysell S.K., Pasipanodya J.G., Gumbo T. Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii // Antimicrob Agents Chemother. – 2023. – Vol. 95, № 5. – Р. e01553-e1620. https://doi.org/10.1128/AAC.01553-20.24Srivastava S., Wang J.Y., Magombedze G., Chapagain M., Huang H.L., Deshpande D., Heysell S.K., Pasipanodya J.G., Gumbo T. Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii. Antimicrob. Agents Chemother., 2023, vol. 95, no. 5, pp. e01553-e1620. https://doi.org/10.1128/AAC.01553-20.24Srivastava S., Deshpande D., Nuermberger E., Lee P.S., Cirrincione K., Dheda K., Gumbo T.The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis // Clinical Infectious Diseases. – 2018. – Vol. 67, S. 3. – Р. 336-341. https://doi.org/10.1093/cid/ciy626Srivastava S., Deshpande D., Nuermberger E., Lee P.S., Cirrincione K., Dheda K., Gumbo T. The sterilizing effect of intermittent tedizolid for pulmonary tuberculosis. Clinical Infection Diseases, 2018, vol. 67, s. 3, pp. 336-341. https://doi.org/10.1093/cid/ciy626Strydom N., Ernest J.P., Imperial M., Solans B.P., Wang Q., Tasneen R., Tyagi S., Soni H., Garcia A., Bigelow K., Gengenbacher M., Zimmerman M., Xie M., Sarathy J.P., Yang T.J., Dartois V., Nuermberger E.L., Savic R.M. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen // Nat Commun. – 2024. – Vol. 15, № 1. – Р. 7311. https://doi.org/10.1038/s41467-024-50781-4Strydom N., Ernest J.P., Imperial M., Solans B.P., Wang Q., Tasneen R., Tyagi S., Soni H., Garcia A., Bigelow K., Gengenbacher M., Zimmerman M., Xie M., Sarathy J.P., Yang T.J., Dartois V., Nuermberger E.L., Savic R.M. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Nat. Commun., 2024, vol. 15, no. 1, pp. 7311. https://doi.org/10.1038/s41467-024-50781-4Study Protocol NCT04550832 Available at: ClinicalTrials.gov [Accessed 16.09.2025].Study Protocol NCT04550832 Available: ClinicalTrials.gov Accessed September 16, 2025Tasneen R., Betoudji F., Tyagi S., Li S.Y., Williams K., Converse P.J., Dartois V., Yang T., Mendel C.M., Mdluli K.E., Nuermberger E.L. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis // Antimicrob Agents Chemother. – 2015. – Vol. 60, № 1. – Р. 270-277. https://doi.org/10.1128/AAC.01691-15Tasneen R., Betoudji F., Tyagi S., Li S.Y., Williams K., Converse P.J., Dartois V., Yang T., Mendel C.M., Mdluli K.E., Nuermberger E.L. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob. Agents Chemother., 2015, vol. 60, no. 1, pp. 270-277. https://doi.org/10.1128/AAC.01691-15Wallis R.S., Dawson R., Friedrich S.O., Venter A., Paige D., Zhu T., Silvia A., Gobey J., Ellery C., Zhang Y., Eisenach K., Miller P., Diacon A.H. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis // PLoS One. – 2014. – Vol. 9, № 4. – Р. e94462. https://doi.org/10.1371/journal.pone.0094462Wallis R.S., Dawson R., Friedrich S.O., Venter A., Paige D., Zhu T., Silvia A., Gobey J., Ellery C., Zhang Y., Eisenach K., Miller P., Diacon A.H. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One, 2014, vol. 9, no. 4, pp. e94462. https://doi.org/10.1371/journal.pone.0094462Wallis R.S., Jakubiec W.M., Kumar V., Silvia A.M., Paige D., Dimitrova D., Li X., Ladutko L., Campbell S., Friedland G., Mitton-Fry M., Miller P.F. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers // J Infect Dis. – 2010. – Vol. 202, № 5. – № 745-751. https://doi.org/10.1086/655471Wallis R.S., Jakubiec W.M., Kumar V., Silvia A.M., Paige D., Dimitrova D., Li X., Ladutko L., Campbell S., Friedland G., Mitton-Fry M., Miller P.F. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis., 2010, vol. 202, no. 5, pp. 745-751. https://doi.org/10.1086/655471Wei L., Hong M., Lu M., Qian Y., Li Q., Tang N., Li H., Chang Y., Qiu Y. Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats // Drugs R D. – 2025. – Vol. 25, № 2. – Р. 127-140. https://doi.org/10.1007/s40268-025-00504Wei L., Hong M., Lu M., Qian Y., Li Q., Tang N., Li H., Chang Y., Qiu Y. Safety evaluation of contezolid (MRX-I) versus linezolid in Sprague-Dawley rats. Drugs R D, 2025, vol. 25, no. 2, pp. 127-140. https://doi.org/10.1007/s40268-025-00504Wen S., Gao X., Zhao W., Huo F., Jiang G., Dong L., Zhao L., Wang F., Yu X., Huang H. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China // Int J Infect Dis. – 2021. – № 109. – Р. 253-260. https://doi.org/10.1016/j.ijid.2021.06.055Wen S., Gao X., Zhao W., Huo F., Jiang G., Dong L., Zhao L., Wang F., Yu X., Huang H. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int. J. Infect. Dis., 2021, no. 109, pp. 253-260. https://doi.org/10.1016/j.ijid.2021.06.055WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment: 2022 update. Geneva:World Health Organization, 2022. – ISBN 978-92-4-006312-9.WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment: 2022 update. Geneva, World Health Organization, 2022. ISBN 978-92-4-006312-9.World Health Organization. Global Tuberculosis Report 2023: Drug-resistant TB burden. Geneva: WHO; 2023 Available at: who.int/publications/i/item/9789240083851 [Accessed 11.07.2025].World Health Organization. Global Tuberculosis Report 2023: Drug-resistant TB burden. Geneva, WHO, 2023. Available: who.int›publications/i/item/9789240083851 Accessed July 7, 2025Yu X., Huo F., Wang F., Wen S., Jiang G., Xue Y., Dong L., Zhao L., Zhu R., Huang H. In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China // Infect Drug Resist. – 2021. – № 14. – Р. 4689-4697. https://doi.org/10.2147/IDR.S332835Yu X., Huo F., Wang F., Wen S., Jiang G., Xue Y., Dong L., Zhao L., Zhu R., Huang H. In vitro antimicrobial activity comparison of linezolid, tedizolid, sutezolid and delpazolid against slowly growing mycobacteria isolated in Beijing, China. Infect. Drug Resist., 2021, no. 14, pp. 4689-4697. https://doi.org/10.2147/IDR.S332835Yuan S., Shen D.D., Bai Y.R., Zhang M., Zhou T., Sun C., Zhou L., Wang S.Q., Liu H.M. Oxazolidinone: A promising scaffold for the development of antibacterial drugs // Eur J Med Chem. – 2023. – № 250. – Р. 115239. https://doi.org/10.1016/j.ejmech.2023.115239Yuan S., Shen D.D., Bai Y.R., Zhang M., Zhou T., Sun C., Zhou L., Wang S.Q., Liu H.M. Oxazolidinone: A promising scaffold for the development of antibacterial drugs. Eur. J. Med. Chem., 2023, no. 250, pp. 115239. https://doi.org/10.1016/j.ejmech.2023.115239Yuste J.R., Berto J., Del Pozo J.L., Leiva J. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity // J. Antimicrob. Chemother. – 2017. – Vol. 72, № 2. – Р. 625-628. https://doi.org/10.1093/jac/dkw484Yuste J.R., Berto J., Del Pozo J.L., Leiva J. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. J. Antimicrob. Chemother., 2017, vol. 72, no. 2, pp. 625-628. https://doi.org/10.1093/jac/dkw484Zhanel G.G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F., Gorityala B., Lagacé-Wiens P.R., Rubinstein E., Walkty A., Gin A.S., Gilmour M., Hoban D.J., Lynch J.P., Karlowsky J.A. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens // Drugs. – 2015. – Vol. 75, № 3. – Р. 253-70. https://doi.org/10.1007/s40265-015-0352-7Zhanel G.G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F., Gorityala B., Lagacé-Wiens P.R., Rubinstein E., Walkty A., Gin A.S., Gilmour M., Hoban D.J., Lynch J.P., Karlowsky J.A. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs, 2015, vol. 75, no. 3, pp. 253-70. https://doi.org/10.1007/s40265-015-0352-7Zhang M., Sala C., Dhar N., Vocat A., Sambandamurthy V.K., Sharma S., Marriner G., Balasubramanian V., Cole S.T. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis // Antimicrob Agents Chemother. – 2014. – Vol. 58, № 6. – Р. 3217-3223. https://doi.org/10.1128/AAC.02410-14Zhang M., Sala C., Dhar N., Vocat A., Sambandamurthy V.K., Sharma S., Marriner G., Balasubramanian V., Cole S.T. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, vol. 58, no. 6, pp. 3217-3223. https://doi.org/10.1128/AAC.02410-14

The authors declare that there are no conflicts of interest present.